The invention is related to a pharmaceutical composition, characterized in that it comprises angiotensin II receptor antagonist or a pharmaceutically acceptable salt or ester or racemic mixture thereof with polyvinyl caprolactam- polyvinyl acetate-polyethylene glycol graft copolymer.